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JAMA Clinical Evidence Synopsis 20 
Title: FDG PET-CT for mediastinal staging in patients with potentially resectable non-small cell 21 
lung cancer. 22 
 23 
Clinical question: What is the sensitivity and specificity of PET-CT for detecting mediastinal 24 
lymph node involvement in patients with potentially resectable non-small cell lung cancer 25 
(NSCLC)?  26 
Bottom line: The sensitivity and specificity of (¹⁸F)-2-fluoro-deoxy-D-glucose (FDG) PET-CT 27 
ranged from 0.77-0.81 and 0.79-0.90, respectively, and were related to the brand of scanner, 28 
NSCLC subtype, FDG dose, and country of study origin. These sensitivities and specificities are 29 
not sufficiently accurate to warrant reliance on PET-CT scanning alone to make decisions about 30 
whether or not to  offer about suitability for surgery as a single option for patients with 31 
potentially resectable NSCLC. PET-CT should instead be used to determine whether the next 32 
step should be a biopsy (with endobronchial ultrasound-guided (EBUS) biopsy or 33 
mediastinoscopy) or surgical resection. 34 
Introduction: Therapeutic options for patients with NSCLC are determined in part by the 35 
presence or absence of intrathoracic mediastinal lymph node metastases.   If disease has not 36 
spread beyond the ipsilateral hilar nodes (N1) then proceeding directly to lung resection is an 37 
appropriate therapeutic option.  PET-CT is a non-invasive staging method which is increasingly 38 
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available and used by lung cancer multidisciplinary teams. This systematic review from a 39 
published Cochrane review specifically examined the accuracy of PET-CT in differentiating 40 
N0/N1 (no lymph node involvement or involvement limited to the ipsilateral hilar, peribronchial 41 
or intrapulmonary nodes) from N2/N3 (involvement of ipsilateral mediastinal, subcarinal or 42 
contralateral lymph nodes) disease. 43 
 44 
Evidence Profile:   45 
Number of studies: 45 diagnostic test accuracy studies  46 
Years studies published: 2006-2013  47 
Literature search date: 30 April 2013 48 
Number of patients:  6095 patients with potentially resectable NSCLC   49 
Male: 69.5% Female: 30.5% 50 
Race/ethnicity: Unavailable   51 
Age, mean (range): 63.6 (23-90) years  52 
Setting: Nuclear imaging, radiology and thoracic surgery departments    53 
Countries: United Kingdom, Italy, USA, China, Poland, Canada, Belgium, Egypt, Denmark, 54 
Turkey, South Korea, Taiwan, Japan, France, Germany, Switzerland.  55 
Comparison: Not applicable. 56 
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Gold standard: Pathological confirmation of PET-CT results from mediastinal nodal sampling 57 
via EBUS biopsy, mediastinoscopy, or resection of the primary tumor with lymph node 58 
resection. 59 
Primary outcome measures: Sensitivity and specificity.  60 
Secondary outcome measures: Adverse events.   61 
This evidence comes from a new original Cochrane Collaboration review1. 62 
Summary of Findings: Different criteria were used to define a positive PET-CT in the reviewed 63 
studies. The summary sensitivity and specificity estimates for the 'FDG uptake in the lymph node 64 
> background uptake’ PET-CT positivity criterion (18 studies, N = 2823) were 0.77 (95% CI 65 
0.65-0.86) and 0.90 (95% CI 0.85-0.94), respectively, but the high variability between the studies 66 
means that in practice sensitivity and specificity may differ from these estimates.  67 
The summary sensitivity and specificity estimates for the ‘Maximum Standardized Uptake Value 68 
≥ 2.5’ PET-CT positivity criterion (12 studies, N = 1656) were 0.81 (95% CI 0.70-0.89) and 69 
0.79% (95% CI 0.70-0.87), respectively, and they were also associated with high between-study 70 
variability and uncertainty about the estimates.  71 
Sensitivity and specificity estimates were related to country of study origin, percentage of 72 
participants with adenocarcinoma, FDG dose, brand of PET-CT scanner, and study size 73 
(FIGURE). None of the studies reported on adverse events. 74 
Discussion: The accuracy of PET-CT is insufficient to allow a decision about whether or not to 75 
proceed directly to surgery as a single option in people with potentially resectable NSCLC to be 76 
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based on PET-CT alone. Instead PET-CT can be used to define the need for further 77 
characterisation of mediastinal lymph nodes with minimally invasive sampling or 78 
mediastinoscopy. Sufficient sensitivity and specificity should both be >0.95 because the 79 
consequences of an incorrect evaluation of mediastinal metastases may have a major influence 80 
on outcome. The difference between the two main brands of PET-CT scanner is important and 81 
may influence the detection of nodal involvement and consequently treatment decisions in some 82 
circumstances. The differences in PET-CT accuracy between scanner brands, NSCLC subtypes, 83 
FDG dose, and country of study origin, along with the variability of results, suggest that all large 84 
centres should monitor their accuracy against the gold standard of pathological confirmation.  85 
 86 
Limitations: The high level of heterogeneity may be partly explained by the variation in the 87 
criteria used for test positivity. Few studies examined the sensitivity and specificity of PET-CT 88 
in lymph nodes that were not significantly enlarged by CT criteria or in populations with a high 89 
prevalence of comorbidities or exposures known to produce false positive results (e.g. 90 
tuberculosis and industrial dust exposure).  91 
Comparison of findings with current practice guidelines: Findings from this systematic review 92 
are consistent with the practice guidelines from the National Institute for Health and Clinical 93 
Excellence, Scottish Intercollegiate Guidelines Network, European Society of Thoracic Surgeons 94 
and American College of Chest Physicians2-5. These guidelines do not recommend the use of 95 
PET-CT alone: When PET-CT is positive, these guidelines recommend that mediastinal 96 
sampling should be performed with EBUS or mediastinoscopy; when the nodes are small (<10 97 
mm) or not visualized by PET-CT, lung resection without mediastinoscopy may be pursued, but 98 
systematic nodal dissection is recommended as part of the surgery    99 
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Areas in need of future study: It is not known how different PET-CT scanners perform in 100 
populations with a  high prevalence of tuberculosis or industrial dust exposure or in populations 101 
with lymph nodes of different sizes.  102 
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Figure legend: Meta-analysis by Subgroup for sensitivity and specificity of PET-CT for 130 
Mediastinal Staging in Patients With Non-Small Cell Lung Cancer (“Criteria for test positivity” 131 
refers to the criteria used by the studies to define a positive PET-CT result; SUVmax = 132 
maximum standardized uptake value of FDG; “mixed” brand of scanner refers to studies that 133 
used more than one brand of PET-CT scanner for obtaining the study data, but collapsed the data 134 
across all the brands used). Adapted with permission from John Wiley & Sons, Inc.  135 

